Differential secretome analysis of cancer‐associated fibroblasts and bone marrow‐derived precursors to identify microenvironmental regulators of colon cancer progression
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The identification of cancer‐associated fibroblast (CAF)‐derived proteins that mediate interactions between the tumor stroma and cancer cells is a crucial step toward the discovery of new molecular targets for therapy or molecular signatures that improve tumor classification and predict clinical outcome. CAF are α‐smooth muscle actin positive, representing a myofibroblast phenotype that may differentiate from multiple precursor cells, including bone marrow‐derived mesenchymal stem cells (MSC). Transforming growth factor‐β1 (TGF‐β1) is a crucial inducer of α‐smooth muscle actin positive CAF s. In this study, we aimed to identify CAF‐derived regulators of colon cancer progression by performing a high‐throughput differential secretome profiling between CAF compared to noncancer‐activated bone marrow‐derived MSC. In addition, we explored the effect of TGF‐β1 on the secretion of proteins by bone marrow‐derived MSC in comparison with the protein secretion profile of CAF. TGF‐β1 induced de novo secretion of 84 proteins in MSC, of which 16 proteins, including stromal‐derived factor‐1α and R antes, were also present in CAF secretome. Immunohistochemistry further validated the expression of selected candidates such as tenascin C, fibronectin ED‐A domain and stromal‐derived factor‐1 in clinical colon cancer specimens. In conclusion, this differential secretome approach enabled us to identify a series of candidate biomarkers for colon cancer that are associated with a CAF‐specific phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206 · cited 2×
“Bone marrow-derived mesenchymal stem cells (MSC) develop myofibroblast characteristics in response to TGF- 1 [6] and localize to solid tumors after intravenous administration in animal models [7, 8].”
BackgroundRole of tissue stroma in cancer cell invasion
De Wever, O., & Mareel, M. (2003) · The Journal of Pathology · doi:10.1002/path.1398 · Cited by 1,042 · cited 1×
“The development of an altered stromal microenvironment in response to carcinoma is an early event during carcinogenesis and a prerequisite for tumor invasion and metastasis [2].”
BackgroundSpaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Stromal myofibroblasts are drivers of invasive cancer growth
De Wever, O., Demetter, P., Mareel, M., & Bracke, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23925 · Cited by 722
Self-citationDe Wever, O., Nguyen, Q., Van Hoorde, L., Bracke, M., Bruyneel, E., Gespach, C., & Mareel, M. (2004) · The FASEB Journal · doi:10.1096/fj.03-1110fje · Cited by 402 · cited 3×
“Previously, we have shown that phenotypically normal colon-derived fibroblasts secrete HGF and that rTGF- 1 treatment maintains HGF secretion and induces TNC secretion [4].”
BackgroundResultSelf-citation
Cited by
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774
Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P., & Shields, J. D. (2018) · Nature Communications · doi:10.1038/s41467-018-03347-0 · Cited by 578
Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts
Ziani, L., Chouaib, S., & Thiery, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00414 · Cited by 381
Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer
Unterleuthner, D., Neuhold, P., Schwarz, K., Janker, L., Neuditschko, B., Nivarthi, H., Crncec, I., Kramer, N., Unger, C., Hengstschläger, M., et al. (2020) · Angiogenesis · doi:10.1007/s10456-019-09688-8 · Cited by 299
Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance
Tuomisto, A. E., Mäkinen, M. J., & Väyrynen, J. P. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i31.4383 · Cited by 271
Yamauchi, M., Barker, T. H., Gibbons, D. L., & Kurie, J. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93554 · Cited by 270
Regulation of the anti-tumour immune response by cancer-associated fibroblasts
Harper, J., & Sainson, R. C. A. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.005 · Cited by 268
The wound healing, chronic fibrosis, and cancer progression triad
Rybinski, B., Franco-Barraza, J., & Cukierman, E. (2014) · Physiological Genomics · doi:10.1152/physiolgenomics.00158.2013 · Cited by 253
Deng, L., Jiang, N., Zeng, J., Wang, Y., & Cui, H. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.733270 · Cited by 51
“SDF1 ECM glycoprotein ECM protein Chemokine Human CRC specimen De Boeck et al., 2013 ECM, extracellular matrix; CDH11, cadherin-11; ADAMs, a disintegrin and metalloproteinases; ncRNAs, non-coding RNAs; ED-A FN, fibronectin ED-A domain; SDF1, stromal-derived factor-1. from these proteins, CAFs from…”
BackgroundFotsitzoudis, C., Koulouridi, A., Messaritakis, I., Konstantinidis, T., Gouvas, N., Tsiaoussis, J., & Souglakos, J. (2022) · Cancers · doi:10.3390/cancers14184394 · Cited by 46
Metadata
- Authors
- De Boeck, A., Hendrix, A., Maynard, D., Van Bockstal, M., Daniëls, A., Pauwels, P., Gespach, C., Bracke, M., & De Wever, O.
- Venue
- PROTEOMICS
- Publisher
- Wiley
- Published
- 2013-01
- Volume
- 13
- Issue
- 2
- Pages
- 379-388
- ISSN
- 1615-9853 (ISSN-L)
- 1615-9861
- OpenAlex
- W1972196680
- Cited by
- 105
- References
- 7
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.